Compare Five9 Inc (FIVN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs BIO-TECHNE Corp — how do they compare? Five9 Inc trades at $32.8 (market cap $2.57B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 4.4× Five9 Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| FIVN | TECH | |
|---|---|---|
Market Cap | $2.57B | $11.24B |
Sector | Technology | Health |
52-Week High | $34.48 | $72.29 |
52-Week Low | $13.61 | $43.31 |
Enterprise Value | $2.73B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $33.99, up 19.81% in 24 hours and near its 52-week high of $34.58, driven by strong Q2 2026 earnings beats and bullish technical signals. Revenue growth accelerated to 10% year-over-year in Q2 2026, with net income turning positive in 2025 after prior losses. Analyst consensus is overwhelmingly positive, with 61% recommending Buy.
The outlook is favorable due to sustained revenue growth and margin expansion, but risks include high valuation multiples and potential overbought conditions. Upside is supported by institutional buying and AI-driven CX demand, though legal scrutiny and debt levels warrant caution.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
